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Abstract
The Transplant Centers belonging to Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) conducted a survey with
the aim of evaluating the effect of SARS-CoV2 pandemic on the allogeneic transplant activity in Italy. The pandemic period
from 1/3/2020 to 31/7/2020 was compared with the same period in 2019. Overall, in 2020 there was a 2.4% reduction in the
number of allo-HCT cases compared to 2019. Interestingly, this deflection did not affect the acute leukemia cases (+5.7% in
2020). The use of peripheral blood-derived stem cells (+10.7%) and cryopreservation (97.4% of the centers) was highly
adopted in 2020. Despite the sanitary emergency, almost all of the surveyed centers declared no impact of SARS-CoV2
pandemic on the transplant timing and outcomes, and the sanitary policy was positively evaluated by the majority of centers.
The emergency measures ensured that only a minority of the allo-HCT patients had been infected by SARS-CoV2; however,
a mortality of 42.1% among the allo-HCT patients hospitalized for COVID-19 was recorded. This survey gives us the
information that the GITMO Group reacted positively to the pandemic. Thanks to the emergency strategies, the Italian allo-
HCT activity continued safely, showing only a minor deflection and offering the same probability of cure to the transplanted
patients.
The SARS-CoV2 pandemic dramatically affected the health
activities. In Italy, as well as in the majority of the Countries,
efforts have been made to guarantee treatments for acute and
oncological patients. This is the case of onco-hematological
patients submitted or candidate to allogeneic hematopoietic
stem cell transplantation (allo-HCT) [1]. Starting from 24th
February, 2020, date on which the first COVID-19-positive
patient has been identified in Italy, decrees and recommen-
dations have been released by the National and International
Health Authorities in order to provide adequate medical
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2%20%282020-03-16%29.pdf). The most relevant ones
allowed the transfer of a donor search from the international
to the national bank registry (IBMDR) and the possibility to
cryopreserve hematopoietic stem cells (HSCs), when there
was concern that the donor was at high risk of community-
acquired infection between work-up and collection (Supple-
mentary Table 1).
On behalf of Gruppo Italiano per il Trapianto di Midollo
Osseo (GITMO), we designed a specific Survey (Trans-
COVID-19 Survey), consisting of 40 multiple choices
questions in order to investigate the effects of SARS-CoV2
pandemic on the Italian Transplant Centers activity. The
first pandemic wave (from March 2020 the 1st to July 2020
the 31st) was compared to the same period of the year 2019.
Five different items were investigated: (I) the transplant
activity in terms of numbers and characteristics of transplant
procedures; (II) the opinion of Centers regarding transplant
outcome in COVID-19 era; (III) the number of subjects
infected by SARS-CoV2 virus among allo-HCT patients
and staff personnel; (IV) the future transplant perspectives,
and (V) the grade of satisfaction about the National and
International recommendations.
The survey was completed by a total of 39/47 (83.0%)
allogeneic transplant Centers, with 100% valid answers. In
addition, eight GITMO-affiliated autologous transplant
Centers sent information on the total number of autologous
transplant procedures in order to evaluate the impact of the
pandemic in the autologous setting. Overall, they declared
51 auto-transplant in 2020 compared to 60 in 2019 (−15%
decrease). No more analyses were carried out in auto-
transplant category (Supplementary Tables 2 and 3a–e).
Taking into account the Italian allo-HCT activity, there
was only a mild decline in the numbers of allo-HCT com-
pared to the same period of the previous year (−2.4%)
(Table 1). Interestingly, the reduction mostly affected less
aggressive diseases, such as lymphoma and myeloma, as
well as autologous procedures, while an increase in the
number of allo-HCT for acute leukemias (+5.7%) was even
observed. The reason for this observation may be well-
explained by the different allo-HCT urgency of such dis-
eases [3, 4]. The effect of SARS-CoV2 pandemic did not
apparently impact on the algorithm of donor’ choice.
Indeed, in the large majority of cases, the Centers did not
change their donor selection policies: sibling, unrelated,
haploidentical and cord blood stem cell source distribution
slightly changed during the pandemic. Nevertheless,
more frontline haploidentical donors were reported and a
higher proportion of unrelated donors (UD) refused to
donate for potential donation-related infectious risk. In
order to maintain the donor selection and transplant stan-
dards, while ensuring the safety of patients undergoing
conditioning therapy in case of unexpected donor unavail-
ability, more UD were recruited by IBMDR and a sig-
nificant increase in the use of peripheral blood-derived stem
cells (PBSC) (+10.9%) and PBSC cryopreservation
(employed in 38 [97.4%] in 2020 vs 19 Centers [48.7%] in
2019) was observed, as recommended by the Health
Authorities [5, 6].
Besides the raw numbers of transplant procedures, 23
centers (59.0%) retained that SARS-CoV2 pandemic had no
impact on transplant timing, while only 2 Centers (5.1%)
declared mild to significant reduction of transplant timing
and 14 (35.9%) an increase in the interval from the first
patient evaluation to transplant. Altogether, these observa-
tions may reflect the efforts of allo-HCT transplant Centers
Table 1 Comparison of transplant characteristics between March–July
2019 and March–July 2020.
2019 N° 2020 N° Variation
N° %




281 297 +16 +5.7
Myelodysplastic
Syndrome
41 40 −1 −2.4
Myeloproliferative
Neoplasms
35 33 −2 −5.7
Hodgkin Lymphoma 14 13 −1 −7.1
Non-Hodgkin Lymphoma 41 26 −15 −36.6
Multiple Myeloma 12 9 −3 −25.0
Non-neoplastic
hematological diseases
38 34 −4 −10.5
Oncological neoplasia 0 1 +1 NA
Type of Donor:
Sibling 108 112 +4 +3.7
Unrelated Donor 218 216 −2 −0.9
Haploidentical 127 116 −11 −8.6
Cord Blood 9 9 0 0
Source HSC:
Peripheral Blood 339 376 +37 +10.0
Bone Marrow 114 66 −48 −42.1
Cord Blood 9 9 0 0
Number of unrelated donor
searches
405 412 +7 +1.7
Shift from Foreign to
Italian Donor
1 16 +15 +1500
Donor IC withdrawal 4 10 +6 +150
Frontline Haplo transplant 33 37 +4 +12.1
Unrelated Donor not
available
4 12 +8 +200
IC informed consent, NA not available.
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to guarantee the transplant continuity. In doing so, whilst in
2019 almost all Center (35/39, 89.7%) did not use tele-
medicine, 31 centers (79.5%) declared telemedicine
employment during the pandemic: notably, in 14 out of 31
centers (45.2%) telemedicine was extended to ≥25% of
ambulatory visits. Moreover, in the opinion of the large
majority of the interviewed Centers, there was no effect of
the pandemic on the transplant-related outcomes.
Eighteen allo-HCT Centers (46.2%) managed hemato-
logical patients with COVID-19. The rate of hematological
SARS-CoV2 positive patients was generally low (1–9 cases
for 88,9% of involved Centers). However, among the hos-
pitalized allo-HCT SARS-CoV2-positive patients the mor-
tality rate was particularly high (8 cases out of 19, 42.1%).
In 9 Transplant Centers (23.1%) personnel redistribution
was requested to provide assistance to non-hematologic
SARS-CoV2-positive patients. Regarding SARS-CoV2-
infected personnel, 22 Centers (56.4%) referred staff
members to be infected by SARS-CoV2 virus, for a total of
79 individuals. Seven out of 79 subjects (8.9%) required
hospitalization in three centers (7.7%) with no fatalities.
The isolation measures well limited the spread of the
infection among allo-HCT patients. Nevertheless, the virus
confirmed its severe impact on immune-depressed patients,
with a mortality higher than 40% among the hospitalized
transplant subjects, as recently reported by an Italian mul-
ticenter study [7]. Also, SARS-CoV2 pandemic had a sig-
nificant impact on the staff personnel too, highlighting once
again the psychological and physical implications of the
pandemic among the hospital professionals.
The latter part of the survey relied on possible transplant
perspectives after the end of SARS-CoV2 crisis. For 28
Centers (71.8%), an extended PBSC utilization could be
maintained or even increased in the early future; on the
contrary, PBSC cryopreservation was expected to return to
pre-SARS-CoV2 era by 16 (41.0%) Centers, while 13
Centers (33.3%) and 10 Centers (25.6%) foresaw only a
mild decrease or stabilization. For 28 (71.8%) Centers the
preferential use of Nationals donors compared to foreign
donors will be maintained (15, 38.5%) or even increased
(13, 33.3%). A total 16 Centers (41.0%) predicted a stabi-
lization or increase in the use of telemedicine, while 12
(30.8%) and 11 (28.2%) Centers hypothesized a slight or
significant reduction, respectively.
Finally, the Centers reported a positive judgement of
indications and recommendations provided by Italian and
European Health Authorities; overall, as confirmed by the
first Survey’s section, the recommendations effectively gui-
ded the Italian transplant activity by all the surveyed Centers.
What is going to remain after this experience in the
future? The opinion poll considered the emergency mea-
sures as the cryopreservation of HSCs, the use of tele-
medicine useful but temporary in the majority of cases.
Long-term analyses are required to confirm the safety and
efficacy of such approach in normal clinical practice.
In conclusion, this survey suggests that collaborative
network between Health Authorities, Scientific Societies
and Transplant Centers ensured to continue a safe transplant
activity among GITMO-affiliated Centers.
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